Empyema News and Research

RSS

Pediatric invasive group A Streptococcal infections on the rise during respiratory virus outbreak

Researchers assess the incidence of invasive Group A streptococcal infections among children before and after the COVID-19 pandemic.

12 Apr 2023

The impact of PLEX on the survival of patients with severe COVID-19 and the effect on the cytokine release syndrome

Researchers evaluated the survival benefit conferred by PLEX in patients with severe COVID-19 and cytokine-storm syndrome.

14 Mar 2022

Patients undergoing neurosurgical operations with concomitant COVID-19 infection have higher rates of perioperative complications

This unique paper compares neurosurgical patients with COVID-19 for perioperative complications to those without COVID-19.

31 Jan 2022

Phenome study reveals alternate associations with SARS-CoV-2 risk loci

Researchers from the Duke Molecular Physiology Institute have been investigating genetic associations with more severe disease and examining the associations that certain genetic features have with other diseases.

13 Dec 2021

New vaccine, enhanced surveillance needed to combat childhood pneumonia

A rise in vaccine-resistant bacteria shows the need for a new vaccine to fight childhood empyema after a spike in hospitalisations, a new UNSW study reveals.

25 Feb 2021

Why improved pneumonia diagnosis is needed now more than ever

News-Medical speaks to Dr. William La Via about why improved pneumonia diagnosis is vital, especially in the wake of the COVID-19 pandemic.

16 Jun 2020

Researchers show that separate septic and aseptic procedure rooms is unnecessary

In Germany, the rule still applies that aseptic and septic and procedure rooms need to be separate; this is a requirement imposed by the Accident Insurance Provider for Hospitals.

8 Sep 2017

AATS releases new Consensus Statement for better management of empyema

To better manage empyema in the face of rising demand for treatment, the American Association for Thoracic Surgery Guidelines Committee called for the formation of the Empyema Management Guidelines Working Group.

20 Apr 2017

Pneumonia in COPD patients has distinct clinical features

The aetiology and clinical features of community-acquired pneumonia are different in people with chronic obstructive pulmonary disease than in those without the lung condition, Spanish research demonstrates.

22 Sep 2014

Albumin may prove a predictor for pneumonia outcomes

Researchers say that assessing serum albumin levels within 24 hours of admission could be a good prognostic marker of community-acquired pneumonia.

21 Jan 2013

PCV13 offers best overall protection from CAP in young children

Researchers have identified a pneumococcal conjugate vaccine that is effective for treating bacteremic pneumococcal community-acquired pneumonia in children aged 5 years or younger.

9 Jul 2012

ICS may prevent parapneumonic effusion in patients with CAP

Prior treatment with inhaled corticosteroids in patients with respiratory disorders who develop community acquired pneumonia (CAP) is associated with a lower incidence and severity of parapneumonic effusion, according to a new study from researchers in Spain.

24 May 2012

H1N1 linked to increased rate of empyema in children

The H1N1 influenza pandemic has led to a sharp increase in the number of children with a serious "secondary" bacterial infection called empyema in children, suggests a study in the October issue of The Pediatric Infectious Disease Journal. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

25 Oct 2010

Study finds PCV7 vaccine reduces bacterial pneumonia infection in children

The number of children admitted to English hospitals with bacterial pneumonia decreased by a fifth in the two years following the introduction of a vaccine to combat the disease, according to a new study published today in the journal Thorax.

27 Aug 2010

PCV-7 vaccine introduction leads to changing patterns of hemolytic uremic syndrome

Introduction of the PCV-7 vaccine to prevent invasive pneumococcal disease (IPD) has led to a shift in the types of bacteria causing hemolytic uremic syndrome (HUS)—an important cause of acute kidney failure in children, reports a study in the August issue of The Pediatric Infectious Disease Journal.

4 Aug 2010

Pneumococcal conjugate vaccine appears to reduce pneumonia, serious complications in infants: Research

A pneumococcal conjugate vaccine introduced in the U.S. 10 years ago appears to reduce pneumonia and serious associated complications, such as blood infections, in the vaccine's target range, children less than a year old, according to new research.

19 Jul 2010

Health Canada recommends new pneumococcal vaccine for young children

In December, 2009, Health Canada approved a new vaccine for children aged six weeks through five years to prevent infections caused by the bacteria called pneumococcus or Streptococcus.

29 Jun 2010

FDA approves Sagent's bacitracin for pneumonia and empyema

Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced FDA approval of bacitracin for injection, USP (bacitracin), an anti-infective product used to treat pneumonia and empyema. Bacitracin will be offered in a 50,000 MU, AP-rated, preservative-free, latex-free, single-dose vial packaged both individually and in packages of ten.

13 May 2010

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine

Pfizer Inc. announced today that the United States Food and Drug Administration has granted approval for Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company’s 13-valent pneumococcal conjugate vaccine.

25 Feb 2010

Health Canada approves Prevnar 13 vaccine for invasive pneumococcal disease

Following a Priority Review, Health Canada has approved Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)) for children aged six weeks through five years for active immunization against invasive pneumococcal disease, a bacterial infection that can include meningitis (inflammation of the coverings of the brain and spinal cord), sepsis (bloodstream infection), bacteremic pneumonia, pleural empyema (accumulation of pus in the cavity surrounding the lungs) and bacteremia (bacteria in the blood).

22 Dec 2009